Neridronate inhibits angiogenesis in vitro and in vivo

  • Ribatti D
  • Nico B
  • Mangieri D
 et al. 
  • 3


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


The effects of the amino-bisphosphonate neridronate on endothelial cell functions involved in angiogenesis, namely, proliferation and morphogenesis on Matrigel were tested in vitro, whereas its effects on angiogenesis were studied in vivo, by using the chick embryo chorioallantoic membrane (CAM) assay. In vitro, neridronate inhibited endothelial cell proliferation in a dose-dependent fashion, peaking at 30 microM. At the same concentration, neridronate inhibited fibroblast growth factor-2 (FGF-2)-induced capillary-like tube formation in the morphogenesis assay on Matrigel. In vivo, when tested in the CAM assay, neridronate again displayed the capability to inhibit FGF-2-induced angiogenesis. Overall, these results suggest that anti-angiogenesis by neridronate could be used to treat a wide spectrum of angiogenesis-dependent diseases, including certain chronic inflammatory diseases and cancer.

Author-supplied keywords

  • Angiogenesis Inhibitors/*pharmacology
  • Animals
  • Capillaries/cytology/drug effects/growth & develop
  • Cell Proliferation/drug effects
  • Cells, Cultured
  • Chick Embryo
  • Chorioallantoic Membrane/blood supply/drug effects
  • Diphosphonates/*pharmacology
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular/cytology/*drug effects/growt
  • Humans
  • Laminin
  • Neovascularization, Physiologic/*drug effects
  • Umbilical Veins/cytology/drug effects

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • D Ribatti

  • B Nico

  • D Mangieri

  • N Maruotti

  • V Longo

  • A Vacca

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free